The correlation of CA15.3 and TPS with tumor course in patients with metastatic breast cancer

Journal of Cancer Research and Clinical Oncology

Volumn 123, Issue 2, 1997, Pages 128-132

  Pronk, Linda C ^a   Stoter, Gerrit ^a   Van Putten, Wim L J ^a   De Wit, Ronald ^a  

^a ERASMUS MC CANCER INSTITUTE   (Netherlands)

Author keywords

breast cancer; CA15.3; TPS; tumor markers

Indexed keywords

CA 15-3 ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; BREAST CANCER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL;

ADULT; AGED; BREAST NEOPLASMS; CA-15-3 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0031040324     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01269892     Document Type: Article

References (18)

1. Barak M, Steiner M, Finker B, Abrahamson J, Antal S, Gruener N (1990) CA15.3, TPA and MCA as markers for breast cancer. Eur J Cancer 26:577-580
2. Beveridge RA, Chan DW, Bruzek D, Damron D, Bray KR, Gaur PK, Ettinger DS, Rock RC, Shurbaji MS, Kuhadja FP (1988) A new biomarker in monitoring breast cancer: CA549. J Clin Oncol 6:1815-1821
3. Bieglmayer C, Szepesi T, Neunteufel W, Nowotny C (1989) MCA, a monoclonal antibody-defined breast tumor-associated antigen and its relation to CA15.3. Tumour Biol 10:232-242
4. Björklund B, Björklund V (1957) Antigenicity of pooled human malignant and normal tissue by cytoimmunological technique: presence of an insoluble, heat-labile tumor antigen. Int Arch Allergy 10:153-184
5. Björklund B, Björklund V, Brunkener M, Gronlund H, Back M (1987) The enigma of a human tumor marker: TPA revisited. In: Cimino F, Birkmayer GD, Klavins JV, Pimentel E, Salvatore F (eds) Human tumor marker. Walter de Gruyter, Berlin, pp 169-180
6. Buamah PK, Bent DJ, Bodger WAH, Skillen AW (1993) A profile of serum CA15.3, carcinoembryonic antigen, alkaline phosphatase, and γ-glutamyl transferase levels in patients with breast cancer. J Surg Oncol 53:84-87
7. Hayes DF, Zurowski VR, Kufe DW (1986) Comparison of circulating CA15.3 and carcinoembryonic antigen levels in patients with breast cancer. J Clin Oncol 4:1542-1550
8. Hilkens J, Buijs F, Hageman Ph, Calagat J, Sannenberg A, Valk M van der (1984) Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors. Int J Cancer 34:197-206
9. Miserez AR, Gunes I, Muller-Brand J, Walther E, Fridrich R, Macke H (1991) Clinical value of a mucin-like carcinoma-associated antigen in monitoring breast cancer patients in comparison with CA15.3. Eur J Cancer 27:126-131
10. Nicolini A, Ferdeghini M, Colizzi C (1993) Evaluation of CEA, TPA, CA 15.3, CA 549 and TPS in the monitoring of metastatic breast cancer. J Nucl Biol Med 37:126-133
11. Pons-Anicet DMF, Krebs BP, Mira R, Namer M (1987) Value of CA15.3 in the follow-up of breast cancer patients. Br J Cancer 55:567-569
12. Soletormos G, Nielsen D, Schioler V, Skovsgaard T, Winkel P, Mouridsen HT, Dombernowsky P (1993) A novel method for monitoring high-risk breast cancer with tumor markers: CA15.3 compared to CEA and TPA. Ann Oncol 4:861-869
13. Tondini C, Hayes DF, Gelman R, Henderson C, Kufe WF (1988) Comparison of CA15.3 and carcinoembryonic antigen in monitoring the clinical course of patients with metastatic breast cancer. Cancer Res 48:4107-4112
14. Van Dalen A (1992) TPS in breast cancer - a comparative study with carcinoembryonic antigen and CA15.3. Tumour Biol 13:10-17
15. Van Dalen A, Van der Linden DL, Heering KJ, Blusse Oudalblas A van (1993) How can treatment response be measured in breast cancer patients? Anticancer Res 13:1901-1904
16. Van Dalen A, Heering KJ, Barak V, Peretz T, Cremaschi A, Geroni P, Gion M, Saracchini S, Molina R, Namer M, Stieber P, Sturgeon C, Leonard RCF, Einarsson R (1996) Treatment response in metastatic breast cancer. A multicenter study comparing UICC criteria and tumour marker changes. Breast 5:82-88
17. WHO (1979) Handbook for reporting results of cancer treatment. WHO Offset Publ 48:22-26
18. Wit R de, Hoek FJ, Bakker PJM, Veenhof CHN (1992) A comparison of CA5-549 with CA15.3 and MCA in patients with metastatic breast cancer. Ann Oncol 3:314-315